Protagonist Therapeutics Future Growth
Future criteria checks 5/6
Protagonist Therapeutics is forecast to grow earnings and revenue by 50% and 21.8% per annum respectively. EPS is expected to grow by 44.1% per annum. Return on equity is forecast to be 16.7% in 3 years.
Key information
50.0%
Earnings growth rate
44.1%
EPS growth rate
Biotechs earnings growth | 24.0% |
Revenue growth rate | 21.8% |
Future return on equity | 16.7% |
Analyst coverage | Good |
Last updated | 27 Mar 2024 |
Recent future growth updates
Recent updates
Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Business Is Trailing The Industry But Its Shares Aren't
Apr 13Protagonist Therapeutics: Why I Remain On Sidelines Despite Obvious Promise
Feb 25We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Dec 28We Think Protagonist Therapeutics (NASDAQ:PTGX) Can Afford To Drive Business Growth
Jul 04Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts
Mar 20An Intrinsic Calculation For Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Suggests It's 42% Undervalued
Feb 06We're Not Very Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn Rate
Jun 15Protagonist: Too Many Red Flags
Jun 08Growth Investors: Industry Analysts Just Upgraded Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Revenue Forecasts By 28%
May 11Protagonist Is Still Being Undervalued Like There's Real Risk
Feb 01Companies Like Protagonist Therapeutics (NASDAQ:PTGX) Are In A Position To Invest In Growth
Jan 04Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Just Slashed This Year's Estimates
Aug 06Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Are Reducing Their Forecasts For This Year
Jun 19Protagonist Therapeutics closes $132M capital raise
Jun 18Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy
Jun 03This Is Why Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Can Expect A Bump Up In Their Pay Packet
May 21Protagonist EPS beats by $0.03, beats on revenue
May 04How Many Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Did Insiders Buy, In The Last Year?
Feb 09We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn
Dec 18Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 146 | -47 | -78 | N/A | 3 |
12/31/2025 | 120 | -7 | -34 | 64 | 5 |
12/31/2024 | 208 | 45 | 177 | 194 | 6 |
12/31/2023 | 60 | -79 | -71 | -70 | N/A |
9/30/2023 | N/A | -140 | -119 | -119 | N/A |
6/30/2023 | N/A | -138 | -118 | -117 | N/A |
3/31/2023 | 1 | -140 | -105 | -105 | N/A |
12/31/2022 | 27 | -127 | -109 | -108 | N/A |
9/30/2022 | 35 | -130 | -104 | -103 | N/A |
6/30/2022 | 45 | -133 | -108 | -107 | N/A |
3/31/2022 | 47 | -122 | -118 | -117 | N/A |
12/31/2021 | 27 | -126 | -109 | -108 | N/A |
9/30/2021 | 24 | -108 | -101 | -100 | N/A |
6/30/2021 | 27 | -81 | -88 | -88 | N/A |
3/31/2021 | 31 | -70 | -86 | -85 | N/A |
12/31/2020 | 29 | -66 | -73 | -72 | N/A |
9/30/2020 | 26 | -65 | -68 | -68 | N/A |
6/30/2020 | 17 | -73 | -66 | -66 | N/A |
3/31/2020 | 2 | -83 | -42 | -41 | N/A |
12/31/2019 | 0 | -77 | -42 | -42 | N/A |
9/30/2019 | 0 | -74 | -38 | -37 | N/A |
6/30/2019 | 2 | -66 | -34 | -32 | N/A |
3/31/2019 | 22 | -45 | -52 | -51 | N/A |
12/31/2018 | 31 | -39 | -50 | -50 | N/A |
9/30/2018 | 40 | -28 | -54 | -54 | N/A |
6/30/2018 | 43 | -24 | -5 | -4 | N/A |
3/31/2018 | 31 | -31 | -2 | -1 | N/A |
12/31/2017 | 20 | -37 | 3 | 4 | N/A |
9/30/2017 | 9 | -45 | N/A | 8 | N/A |
6/30/2017 | N/A | -48 | N/A | -39 | N/A |
3/31/2017 | N/A | -40 | N/A | -35 | N/A |
12/31/2016 | N/A | -38 | N/A | -30 | N/A |
9/30/2016 | N/A | -32 | N/A | -25 | N/A |
6/30/2016 | N/A | -28 | N/A | -22 | N/A |
3/31/2016 | N/A | -24 | N/A | -17 | N/A |
12/31/2015 | N/A | -15 | N/A | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PTGX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.4%).
Earnings vs Market: PTGX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PTGX is expected to become profitable in the next 3 years.
Revenue vs Market: PTGX's revenue (21.8% per year) is forecast to grow faster than the US market (8.3% per year).
High Growth Revenue: PTGX's revenue (21.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PTGX's Return on Equity is forecast to be low in 3 years time (16.7%).